Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7486639

Low environmental temperatures or pharmacologic agents that produce hyperthermia decrease methamphetamine neurotoxicity in mice.

S F Ali·R R Newport·W Holson·W Slikker·J F Bowyer
View original source ↗Export metadata ↓

Abstract

The source did not provide an abstract. Follow the original record for more information.

Explore related subjects

3,4-Dihydroxyphenylacetic AcidAnimalsCold TemperatureCorpus StriatumDizocilpine MaleateDopamineHaloperidolHomovanillic AcidHypothermiaHypothermia, InducedMaleMethamphetamineMiceMice, Inbred StrainsNeuroprotective AgentsNeurotoxinsPentobarbitalPhenobarbitalJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S F Ali, R R Newport, W Holson, W Slikker, J F Bowyer. 1995-09-15. Low environmental temperatures or pharmacologic agents that produce hyperthermia decrease methamphetamine neurotoxicity in mice.. https://doi.org/10.1111/j.1749-6632.1995.tb16610.x

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1995

Reduction of dihydroxyphenylacetic acid by a novel enzyme in the rat brain.

A novel enzyme that converts dihydroxyphenylacetic acid (DOPAC) to dihydroxyphenylethanol (DOPET) was found to be present in the microdialysate of the rat brain. The enzyme, named DOPAC reductase, was inhibited by EDTA and stimulated by divalent cations like Zn2+, Mn2+, Co2+ and Cu2+. Its Km, pH optimum and temperature optimum were found to be 32 +/- 2 microM, 7.5 and 40 degrees, respectively. The equivalent acid metabolite of noradrenaline, 3,4-dihydroxymandelic acid, and the methoxylated acids of both noradrenaline and dopamine, 3-methoxy-4-hydroxymandelic acid and 3-methoxy-4-hydroxyphenylacetic acid, were found not to be substrates of DOPAC reductase. Thus, DOPAC reductase may be an enzyme that is specifically involved in the one-step conversion of DOPAC to DOPET in the central metabolism of dopamine.

3,4-Dihydroxyphenylacetic Acid↗
PubMed1995

Neuropeptide Y potentiation of potassium-induced noradrenaline release in the hypothalamic paraventricular nucleus of the rat in vivo.

NPY is co-localised with catecholamines in the brain and periphery. Noradrenaline and NPY are present in high concentrations in the PVN of the hypothalamus, an area implicated in autonomic regulation. This microdialysis study examined whether NPY can modulate rat PVN noradrenaline release in vivo, as has been shown in vitro. Basal and K(+)-stimulated noradrenaline release was measured after i.c.v. administration of 2 nmol NPY or vehicle. No effect of NPY was observed on basal release, however a significant doubling of K(+)-induced release was observed, both 60 and 150 min following i.c.v. NPY. This raises the possibility that NPY may potentiate rather than inhibit brain noradrenaline release in vivo.

3,4-Dihydroxyphenylacetic Acid↗